Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
about
Pharmacological interventions for pain in children and adolescents with life-limiting conditionsBisphosphonate therapy for osteogenesis imperfectaInterventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophySclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesBisphosphonate therapy in pediatric patientsRecognizing and treating secondary osteoporosisThe management of osteoporosis in children.Bisphosphonate treatment for children with disabling conditions.The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutationsRecent advances in osteogenesis imperfecta.Evidence for using bisphosphonate to treat Legg-Calvé-Perthes diseaseA randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.Bisphosphonate therapy for osteogenesis imperfecta.Secondary osteoporosis in patients with juvenile idiopathic arthritis.Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatmentAn update on childhood bone health: mineral accrual, assessment and treatment.Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type IMedication Repurposing in Pediatric Patients: Teaching Old Drugs New TricksTherapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse boneSclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.Bone mineral density in developing children with osteogenesis imperfecta: a longitudinal study with 9 years of follow-up.Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfectaComparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.Skeletal Dysplasias: Growing Therapy for Growing Bones.New perspectives on osteogenesis imperfectaTooth dentin defects reflect genetic disorders affecting bone mineralization.Radiographic features of osteogenesis imperfecta.Osteogenesis imperfecta in adults: phenotypic characteristics and response to treatment in an Irish cohort.Osteogenesis imperfecta: diagnosis and treatment.Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab.The 2 + 1 paradigm: an efficient algorithm for central reading of Mayo endoscopic subscores in global multicenter phase 3 ulcerative colitis clinical trials.Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update.Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.Pediatric Osteoporosis: Diagnosis and Treatment Considerations.Pharmacological and biological therapeutic strategies for osteogenesis imperfecta.An ENU-induced splice site mutation of mouse Col1a1 causing recessive osteogenesis imperfecta and revealing a novel splicing rescue
P2860
Q24187283-AB913271-D348-4A92-9042-A04A9913F8ADQ24194821-87326F53-3BE2-4E51-8CA2-043ACD8DAE44Q24198280-A858C7D3-6E37-4015-90C2-9120A99F4553Q26744599-A11C70E4-3F04-4E92-8761-CCD0622455BAQ26830702-20315AB4-16C3-4398-8BB7-0B11CB8E35FEQ28270738-60C5E384-246C-4BBB-9DEA-FB8718590056Q30251490-DBF7629E-A8F9-42D3-826A-09E5B45B20ACQ33680621-5ED87447-D573-4FF9-AD66-42F0B1E0997DQ33847609-AB5540BE-240F-4523-B5BD-58CB485F79EFQ34031264-4D99C2C8-01E5-4338-9CDD-0A6139C53643Q34249155-2B6A7585-0D1C-40F0-81D5-9745FE0B5710Q34429461-C1968AF2-E8CF-4BF0-BF53-CD0B2B2B2CEFQ34543060-E86D8006-2FE3-4612-AACB-3A3A3B939872Q34595120-0BC2A735-1D79-44BA-BEC6-DF2DF7E3BE8AQ34759279-3C4CBFDF-6135-4D80-B27C-E00326C6BBCCQ35510163-0A21769F-E152-44D4-816B-6FE7163085D5Q36472781-EBFAA8BE-EB9C-4E5E-BF15-950FDB37A751Q36500182-222EF47F-EDC8-4E80-85CB-48ED3708E8F1Q36652800-60CEB1E0-8A68-4A6D-ACC6-96F8CDB0B1FAQ36662940-BC02C692-F2F5-4588-B0D1-95CCF2242C06Q36889245-C8670A65-0B05-4B45-BCA4-BDB503C923B0Q37158425-9000730B-2BC8-47F2-82C0-1ACCB0076126Q37384560-6CC40B6C-3A5B-4256-8421-187D675A43BFQ37523900-A4D70EA8-3BAE-4D08-9136-912ECE47F527Q37579579-9B07E60B-1E66-4AFD-9895-09EBE8607595Q37681118-13BF8DB8-31CB-4457-BA92-D048720369D2Q37889113-F294D510-0683-4588-8EAB-1F93B884BD66Q37980555-1D8F4625-D408-4853-B3B9-2593981B9900Q38107886-88F9C38E-50CC-4F54-9BC2-E131475969BBQ38126878-DB87CC59-DAF1-4CAD-A41C-F3E8F4D2C972Q38223208-5C630CCE-AF5F-4209-8E3D-72A16A36EE13Q38226264-8F684002-3149-4DCA-9E6F-28157535856BQ38561728-EF71DE76-E600-4174-90FD-B0283521D708Q38617388-FCC94598-EF0F-4B8E-8589-C0FC80ACFF7EQ38766431-2FA4CC7F-606E-4DEC-A42B-1628A9DF2F4FQ38902397-6331CC12-B37D-4EC9-9974-F29A06A7BB1FQ38918970-11A7853B-649B-4B1D-B034-2A2DD3E8DE62Q38921958-8DA55F4C-1B75-4127-89A9-57EA7F6D5E05Q38998578-902C7B77-F884-497D-B026-F8A8B0A3BA73Q41718522-4D21FF31-9B61-4264-91C5-E31210587147
P2860
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Alendronate for the treatment ...... ized placebo-controlled study.
@ast
Alendronate for the treatment ...... ized placebo-controlled study.
@en
Alendronate for the treatment ...... ized placebo-controlled study.
@nl
type
label
Alendronate for the treatment ...... ized placebo-controlled study.
@ast
Alendronate for the treatment ...... ized placebo-controlled study.
@en
Alendronate for the treatment ...... ized placebo-controlled study.
@nl
prefLabel
Alendronate for the treatment ...... ized placebo-controlled study.
@ast
Alendronate for the treatment ...... ized placebo-controlled study.
@en
Alendronate for the treatment ...... ized placebo-controlled study.
@nl
P2093
P356
P1476
Alendronate for the treatment ...... mized placebo-controlled study
@en
P2093
A Lombardi
D L Smith-Wright
E L Lester
E Sullivan
F H Glorieux
J D'Astous
J O Sanders
P304
P356
10.1210/JC.2010-0636
P407
P577
2010-11-24T00:00:00Z